Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Summary

Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of relapsing-remitting multiple sclerosis. GA is an immunomodulating drug that has anti inflammatory and neuroprotective properties, which are believed to be of therapeutic value in ALS. The study treatment duration is 1 year (52 weeks).

Timeline

Start

2006-07-27

Primary completion

2008-06-17

Completion

2008-06-17

Drugs

Indications